Key points are not available for this paper at this time.
The FDA does not currently require label statements regarding a product's comparative effectiveness. Dr. Randall Stafford, Todd Wagner, and Philip Lavori propose an expanded labeling requirement that would provide explicit information about proven comparative benefits or lack thereof.
Stafford et al. (Thu,) studied this question.